Boston Trust Walden Corp Sells 200 Shares of CVS Health Corporation (NYSE:CVS)

Boston Trust Walden Corp cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 1.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,428 shares of the pharmacy operator’s stock after selling 200 shares during the quarter. Boston Trust Walden Corp’s holdings in CVS Health were worth $1,045,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hopwood Financial Services Inc. purchased a new stake in shares of CVS Health in the fourth quarter worth $29,000. McIlrath & Eck LLC boosted its holdings in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock worth $32,000 after buying an additional 174 shares during the period. Compass Planning Associates Inc purchased a new stake in CVS Health in the 4th quarter worth $37,000. Providence First Trust Co bought a new stake in CVS Health during the fourth quarter valued at about $42,000. Finally, Park Square Financial Group LLC purchased a new position in shares of CVS Health in the fourth quarter valued at about $43,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 0.2%

Shares of CVS stock opened at $66.69 on Friday. The company has a market cap of $84.36 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 0.96 and a beta of 0.56. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. The stock’s 50 day simple moving average is $64.92 and its two-hundred day simple moving average is $60.40. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $72.51.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. CVS Health’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the company earned $1.31 earnings per share. Research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Guy P. Sansone acquired 1,570 shares of the firm’s stock in a transaction on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the purchase, the director now directly owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.22% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on CVS. Barclays set a $79.00 target price on CVS Health and gave the stock an “overweight” rating in a research report on Monday, June 2nd. Wells Fargo & Company reiterated an “overweight” rating and set a $84.00 price objective (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Royal Bank Of Canada upped their target price on shares of CVS Health from $74.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 5th. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a research note on Tuesday, April 15th. Finally, Truist Financial increased their price objective on shares of CVS Health from $82.00 to $84.00 and gave the company a “buy” rating in a report on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.